While several key molecular pathways, such as FLT3, RAS, and TP53 signaling, have been implicated in AML [6, 7, 8], there is an urgent need to clarify new processes that propel AML advancement in order to uncover new treatment targets and enhance patient outcomes. Here, FLT3 is linked to acute myeloid leukemia.